Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sibofimloc - Enterome/Takeda

Drug Profile

Sibofimloc - Enterome/Takeda

Alternative Names: EB-8018; TAK-018

Latest Information Update: 28 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer Enterome; Takeda
  • Class Anti-inflammatories; Fluorenes; Hepatoprotectants; Ketones; Piperidines; Pyrans; Small molecules; Spiro compounds
  • Mechanism of Action E coli fimH protein inhibitors; Microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease
  • No development reported Gastrointestinal disorders; Liver disorders

Most Recent Events

  • 28 Jun 2023 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in United Kingdom (PO)
  • 28 Jun 2023 No recent reports of development identified for preclinical development in Liver-disorders in United Kingdom (PO)
  • 25 Aug 2022 Takeda terminates the phase IIa SYMMETRY trial in Crohn's disease in Austria, United Kingdom, France, Germany, Netherlands and USA (PO) due to sponsor decision to discontinue study due to inability to recruit the expected number of subjects within the requisite time period (EudraCT2019-000886-19) (NCT03943446)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top